Home › NCT00710177

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

Prostaglandin G/H Synthase-1 (PTGS1) Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN)

Who can join

12 Months · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age.

Exclusion Criteria:

* Patients will be excluded if they are diagnosed with lethal congenital anomalies
* structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale
* structural gastrointestinal tract abnormality that could interfere with meconium passage
* congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia

About the study

The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).

Sponsor: Medical College of Wisconsin · Participants: 200 · Started: 2006-01

Contact the study team

• G. Ganesh Konduri, MD · Phone: 414-266-6820
• Kathleen M Meskin, BSN · Phone: 414-337-7171

Official record on ClinicalTrials.gov — NCT00710177

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.